Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
07 mai 2019 09h15 HE
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...